CXCR2 and neoplasm: By adding a CXCR2 antagonist AZD-5069 in both scenarios, the NTI-chip also enabled us to tease out blockade of soluble factors and blockade of direct cell–cell contact as two different tumor-suppressive mechanisms of CXCR2 inhibition.